Advertisement
Research Article Free access | 10.1172/JCI105687
Department of Medicine, University of Colorado Medical Center, Denver, Colorado
‡A recipient of Career Development Award from the National Institute of Health.
Address requests for reprints to Dr. Y. Takeda, University of Colorado Medical Center, 4200 East Ninth Avenue, Denver, Colo. 80220.
*Received for publication 5 May 1967 and in revised form 8 July 1967.
This work was jointly supported by research grant HE-02262 from the National Heart Institute and research grant FR-00051-05 from the U. S. Public Health Service.
Find articles by Takeda, Y. in: JCI | PubMed | Google Scholar
Department of Medicine, University of Colorado Medical Center, Denver, Colorado
‡A recipient of Career Development Award from the National Institute of Health.
Address requests for reprints to Dr. Y. Takeda, University of Colorado Medical Center, 4200 East Ninth Avenue, Denver, Colo. 80220.
*Received for publication 5 May 1967 and in revised form 8 July 1967.
This work was jointly supported by research grant HE-02262 from the National Heart Institute and research grant FR-00051-05 from the U. S. Public Health Service.
Find articles by Chen, A. in: JCI | PubMed | Google Scholar
Published December 1, 1967 - More info
Using autologous 131I-fibrinogen, we made studies of the metabolism and distribution of fibrinogen in 10 patients with hemophilia A. In two patients simultaneous studies of autologous 131I-fibrinogen and homologous 125I-fibrinogen prepared from healthy donors' plasma were carried out. The average value for the plasma volume was 42.1 ± 8.8 ml/kg; for the plasma fibrinogen concentration, 349 ± 90 mg/100 ml; for the intravascular fibrinogen, 144 ± 32 mg/kg; for the interstitial fibrinogen, 30 ± 11 mg/kg; for the slower half-life of 131I-fibrinogen, 2.34 ± 0.17 days; for the transcapillary transfer rate of fibrinogen, 109 ± 37 mg/kg per day; and for the catabolic and synthetic rates of fibrinogen, 51.7 ± 13.1 mg/kg per day. Comparison of these results with those of the previous study in healthy male subjects showed that in patients with hemophilia A the catabolic and synthetic rates of fibrinogen are markedly increased, whereas the plasma fibrinogen concentration, intravascular and interstitial fibrinogen, and the transcapillary transfer rate of fibrinogen are not significantly different. The simultaneous studies of autologous 131I-fibrinogen and normal homologous 125I-fibrinogen in two subjects revealed that the two preparations behaved very similarly. Based on these findings, we concluded that our present findings are not due to the qualitative difference between the hemophilia A and normal fibrinogens, but that they are due to the difference in the host condition with respect to the fibrinogen metabolism, which is either an increased rate of direct breakdown of fibrinogen or an increased rate of fibrinogen breakdown after fibrin formation, or both.